A platform-agnostic, function first-based antibody discovery strategy using plasmid-free mammalian expression of antibodies

A platform-agnostic, function first-based antibody discovery strategy using plasmid-free mammalian expression of antibodies

Hybridoma technology has been valuable in the development of therapeutic antibodies. More recently, antigen-specific B-cell selection and display technologies are also gaining importance. A major limitation of these approaches used for antibody discovery is the extensive process of cloning and expre...

Full description

Bibliographic Details
Main Authors: Ruijun Zhang, Ponraj Prabakaran, Xiaocong Yu, Brian C. Mackness, Ekaterina Boudanova, Joern Hopke, Jose Sancho, Jacqueline Saleh, HyunSuk Cho, Ningning Zhang, Helene Simonds-Mannes, Samuel D. Stimple, Dietmar Hoffmann, Anna Park, Partha S. Chowdhury, Sambasiva P. Rao
Format: Article
Language:English
Published: Taylor & Francis Group 2021-01-01
Series:mAbs
Subjects:
Antibody discovery
transgenic mouse
single B-cell cloning (SBC)
phage display
monoclonal antibody (mAb)
overlapping PCR
Online Access:https://www.tandfonline.com/doi/10.1080/19420862.2021.1904546

Internet

https://www.tandfonline.com/doi/10.1080/19420862.2021.1904546

Similar Items